Progress across the board at the Van Lanschot Kempen
Conference in Amsterdam
Companies are innovating across the spectrum: new modalities, targets and insights in disease biology. This progress is close to academia and at the leading edge of research.
This can represent huge investment opportunities, but selectivity is key: Not all trials will work, not all companies have the same level of understanding and rigour.
Check out Thoughts from the Street below.
Should you want to know more about our conclusions, please contact us!
